HK1253320A1 - 用於治療aml的藥物組合物和治療有此需要的對象中的aml的方法 - Google Patents

用於治療aml的藥物組合物和治療有此需要的對象中的aml的方法

Info

Publication number
HK1253320A1
HK1253320A1 HK18112613.2A HK18112613A HK1253320A1 HK 1253320 A1 HK1253320 A1 HK 1253320A1 HK 18112613 A HK18112613 A HK 18112613A HK 1253320 A1 HK1253320 A1 HK 1253320A1
Authority
HK
Hong Kong
Prior art keywords
treating aml
subject
need
pharmaceutical composition
aml
Prior art date
Application number
HK18112613.2A
Other languages
English (en)
Inventor
Kenji Nakamaru
Koichi Tazaki
Takahiko Seki
Ngai-Chiu Archie Tse
Michael Andreeff
Jo Ishizawa
Original Assignee
Daiichi Sankyo Co Ltd
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Co Ltd, Univ Texas filed Critical Daiichi Sankyo Co Ltd
Publication of HK1253320A1 publication Critical patent/HK1253320A1/zh

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK18112613.2A 2015-10-23 2018-10-02 用於治療aml的藥物組合物和治療有此需要的對象中的aml的方法 HK1253320A1 (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562245667P 2015-10-23 2015-10-23

Publications (1)

Publication Number Publication Date
HK1253320A1 true HK1253320A1 (zh) 2019-06-14

Family

ID=57349100

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18112613.2A HK1253320A1 (zh) 2015-10-23 2018-10-02 用於治療aml的藥物組合物和治療有此需要的對象中的aml的方法

Country Status (8)

Country Link
US (1) US20180303812A1 (zh)
EP (1) EP3364966A1 (zh)
JP (1) JP2018538247A (zh)
KR (1) KR20180067677A (zh)
CN (1) CN108135884A (zh)
HK (1) HK1253320A1 (zh)
TW (1) TW201722428A (zh)
WO (1) WO2017069288A1 (zh)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Hdac抑制劑與pd-l1抑制劑之組合治療
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
CA3040840A1 (en) * 2016-10-17 2018-04-26 Daiichi Sankyo Company, Limited Combined use of mdm2 inhibitor and dna methyltransferase inhibitor for cancer treatment
CN113286633A (zh) * 2018-10-30 2021-08-20 宏观基因有限公司 用于治疗血液***恶性肿瘤的双特异性CD123 x CD3双抗体
CN111893172A (zh) * 2020-06-24 2020-11-06 南通大学附属医院 Grsf1在判断脓毒症患者严重程度及预后方面的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009120561A2 (en) 2008-03-22 2009-10-01 Merck & Co., Inc. Methods and gene expression signature for assessing growth factor signaling pathway regulation status
WO2012121361A1 (ja) 2011-03-10 2012-09-13 第一三共株式会社 ジスピロピロリジン誘導体
TWI586668B (zh) * 2012-09-06 2017-06-11 第一三共股份有限公司 二螺吡咯啶衍生物之結晶
EP3094746A1 (en) 2014-01-14 2016-11-23 Daiichi Sankyo Company, Limited Gene signatures associated with sensitivity to mdm2 inhibitors

Also Published As

Publication number Publication date
CN108135884A (zh) 2018-06-08
WO2017069288A1 (en) 2017-04-27
EP3364966A1 (en) 2018-08-29
KR20180067677A (ko) 2018-06-20
WO2017069288A8 (en) 2018-04-12
JP2018538247A (ja) 2018-12-27
US20180303812A1 (en) 2018-10-25
TW201722428A (zh) 2017-07-01

Similar Documents

Publication Publication Date Title
IL256085B (en) A substituted derivative of cholanoic acid, a pharmaceutical composition comprising it and the substituted derivative for use in treatment
SG11201706767RA (en) Materials and methods for treatment of hemoglobinopathies
IL251759B (en) Preparations and methods for treating insomnia
HK1253320A1 (zh) 用於治療aml的藥物組合物和治療有此需要的對象中的aml的方法
HK1252663A1 (zh) 亨特綜合征治療劑和治療方法
IL255530A (en) Efflux-pump inhibitors and therapeutic uses thereof
EA033123B9 (ru) Антипролиферативная и антиметастатическая фармацевтическая композиция и способ лечения рака
ZA201703398B (en) Pharmaceutical composition and methods
HK1256541A1 (zh) 用於處理皮膚的方法和組合物
IL249989B (en) Spiritual preparations containing ciclomiphene for use in the method of treating hot flashes
HK1258502A1 (zh) 用於治療高胱氨酸尿症的組合物和方法
ZA201605109B (en) Compositions and methods for treating neutropenia
PL3129057T3 (pl) Glikolipidy i ich kompozycje farmaceutyczne do stosowania w leczeniu
PL3406258T3 (pl) Lek do stosowania w leczeniu dny moczanowej
HK1214767A1 (zh) 片劑形式的藥物組合物及其製造方法
HK1245094A1 (zh) 一種治療抑鬱症的藥物組合物及其製備方法
GB201511799D0 (en) Composition and methods of treatment
IL280389A (en) Bile acid receptor modulators conjugated to G.1 protein and methods of using them
IL249440B (en) Pharmaceutical compounds and preparations containing them for the treatment of neurodegenerative diseases
PT3236961T (pt) Composição farmacêutica para prevenir ou tratar cancro
GB201519644D0 (en) Therapy and pharmaceutical composition
ZA201802201B (en) Novel formulation and treatment methods
IL248847A0 (en) Dosertalin dosage and method for treating adhd
SG11201804140PA (en) Acidic-gas treating agent and acidic-gas treating method
HK1214770A1 (zh) 清痹中藥組合物及其製備方法